1. Establishment and application of recombinase polymerase amplification combined with a lateral flow dipstick for the detection of mcr-1 in uncultured clinical samples.
- Author
-
Feng J, Xu Z, Zhuang Y, Luo J, Chen Y, Wu Y, Fei J, Liu M, Xia J, Zhang J, Liu M, Xie X, Yuan Z, and Chen M
- Subjects
- Recombinases, Humans, Feces microbiology, DNA-Directed DNA Polymerase, Colistin pharmacology, Anti-Bacterial Agents pharmacology, Nucleic Acid Amplification Techniques, Enterobacteriaceae drug effects, Enterobacteriaceae genetics, Enterobacteriaceae isolation & purification, Ethanolaminephosphotransferase analysis, Ethanolaminephosphotransferase genetics, Bacterial Proteins analysis, Bacterial Proteins genetics, Drug Resistance, Bacterial genetics
- Abstract
Objectives: The rapid dissemination of the mcr-1 gene via plasmid-mediated transfer has raised concerns regarding the efficacy of colistin as a last-resort treatment for multidrug-resistant Gram-negative bacterial infections. Current mcr-1 gene detection methods mainly focus on cultured bacteria, which is a complex and time-consuming process requiring skilled personnel, making it unsuitable for field analysis., Methods: A rapid detection technique combining recombinase polymerase amplification with a lateral flow dipstick targeting uncultured clinical samples was developed., Results: This new method targeting the mcr-1 gene region (23 232-23 642 bp, no. KP347127.1) achieved a low detection limit of 10 copies/μL. The whole process was carried out with high specificity and was completed within 20 min. The evaluation assay was conducted using 45 human faecal samples; 16 strains yielded a 98% accuracy, closely matching antimicrobial susceptibility outcomes., Conclusions: The novel method integrates nucleic acid extraction, isothermal amplification, and a test assay, suggesting the potential for timely colistin resistance surveillance in frontline disease control and healthcare settings, supporting future prevention and clinical standardization efforts., (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF